Amjevita Injection
Product Images NDC 84612-482

Product Visual Gallery

This gallery contains 63 technical images submitted to the FDA as part of the official labeling for Amjevita (NDC 84612-482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nuvaila Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amjevita 01)

A line graph depicting percent ACR 20 responders over time in weeks. The x-axis represents time (weeks), and the y-axis shows the percent of responders. Two lines compare treatment with 40 mg every other week and placebo, illustrating response rates across approximately 48 weeks.*

FDA Label Image

Figure 2 (Amjevita 02)

A line graph comparing the percentage of ASAS 20 response over 24 weeks between Adalimumab (N=208) and Placebo (N=107). The x-axis represents time in weeks, and the y-axis represents the percentage response. Adalimumab shows a higher response rate throughout the period compared to Placebo.*

FDA Label Image

Figure 3 (Amjevita 03)

A line graph comparing treatment failure rate percentages over time (in months) between placebo and adalimumab treatments. The x-axis represents time in months, and the y-axis shows treatment failure rate in percent. Two lines indicate cumulative failure rates: a solid line for placebo and a dashed line for adalimumab, with numerical patient data provided below the x-axis for each time point.*

FDA Label Image

Figure 3 (Amjevita 04)

A Kaplan-Meier plot showing treatment failure rate percentage over 20 months comparing placebo and adalimumab treatments. The solid line represents placebo, and the dashed line represents adalimumab, indicating lower failure rates with adalimumab over time. Number of subjects at risk is displayed below the x-axis for each time point.*

FDA Label Image

Image (Amjevita 05)

A labeled instructional diagram of a prefilled syringe for AMJEVITA (adalimumab-atto) injection. It identifies parts including the plunger rod, finger grip, expiration date, syringe body, plunger (noting location may vary), medicine inside the syringe, and needle cap containing the needle.*

FDA Label Image

Image (Amjevita 06)

An illustration showing a subcutaneous injection pen device with a plunger, a handle, and a protective tip at the needle end. The device is designed for self-administration of medication such as AMJEVITA (adalimumab-atto) injection.*

FDA Label Image

Image (Amjevita 07)

An illustration of a prefilled syringe with a blue plunger and a white body, designed for subcutaneous injection. The syringe includes a wide, flat grip area near the top and a grey needle cap at the bottom.*

FDA Label Image

Image (Amjevita 08)

Illustration of a subcutaneous injection device, likely an auto-injector or syringe, used for administering a medication such as AMJEVITA (adalimumab-atto). The device shows a plunger, barrel, and needle cover with no visible labeling or dosage information on the device itself.*

FDA Label Image

Image (Amjevita 09)

An instructional illustration showing how to fold and store the product carton. Includes a blue arrow pointing to the carton with the instruction text 'Refrigerate in carton until ready to use.'*

FDA Label Image

Image (Amjevita 10)

An instructional illustration showing a hand retrieving a prefilled syringe from a tray, with a close-up inset highlighting the syringe and an arrow pointing upward, indicating a step in preparing or administering the AMJEVITA (adalimumab-atto) injection for subcutaneous use.*

FDA Label Image

Image (Amjevita 11)

An illustration of a clock face indicating a time range of 15 to 30 minutes, likely representing a time interval.*

FDA Label Image

Image (Amjevita 12)

An illustration of a blue and white calendar page showing the number '14' in large black font above the word 'days,' emphasizing a two-week time period.*

FDA Label Image

Image (Amjevita 13)

An instructional diagram showing a sharps disposal container alongside common injection supplies: an alcohol wipe, an adhesive bandage, and a cotton ball or gauze pad. These items are labeled for use in proper injection site care and sharps disposal.*

FDA Label Image

Image (Amjevita 14)

An illustration showing a prefilled syringe injection device with a labeled close-up of the medicine contained in the syringe barrel. The syringe is designed for subcutaneous injection, consistent with the injection dosage form of AMJEVITA (adalimumab-atto).*

FDA Label Image

Image (Amjevita 15)

An instructional diagram illustrating the location of the expiration date on the AMJEVITA adalimumab-atto prefilled injection device. The expiration date is shown on a black label near the top side of the device.*

FDA Label Image

Image (Amjevita 16)

An instructional illustration showing recommended injection sites for subcutaneous administration. The highlighted areas include the abdomen and the front of the thighs, with blue shaded regions indicating appropriate locations for injection.*

FDA Label Image

Image (Amjevita 17)

An instructional illustration showing two hands washing with soap and water, with bubbles around the fingers indicating lathering. The image emphasizes proper handwashing technique.*

FDA Label Image

Image (Amjevita 18)

An instructional illustration showing a hand pressing down on a small adhesive patch, likely representing the proper application technique for a subcutaneous injection site preparation related to AMJEVITA (adalimumab-atto) injection.*

FDA Label Image

Image (Amjevita 19)

An instructional illustration showing a person holding the cap of a syringe in one hand and the syringe itself in the other hand, with an arrow indicating the action of removing the syringe cap prior to injection.*

FDA Label Image

Image (Amjevita 20)

An instructional illustration showing a can with an open tab and a black stick or object being inserted into the opening. A blue arrow indicates the direction of insertion.*

FDA Label Image

Image (Amjevita 21)

An instructional illustration showing how to pinch the skin at the injection site on the arm for a subcutaneous injection. The image depicts a hand pinching the skin on the forearm, labeled 'PINCH skin at injection site.'*

FDA Label Image

Image (Amjevita 22)

An instructional illustration showing the proper injection technique with a syringe held at a 45-degree angle, aimed at the skin of a hand or wrist. The image emphasizes the angle and placement for subcutaneous injection.*

FDA Label Image

Image (Amjevita 23)

An instructional illustration showing a hand holding a syringe at a 90-degree angle to the skin surface, indicated by a blue arrow. The syringe is shown administering a subcutaneous injection into the forearm of another hand, demonstrating proper injection technique.*

FDA Label Image

Image (Amjevita 24)

Illustration showing a hand holding a syringe injecting into a vial with an open lid, indicating the process of drawing medication from the vial into the syringe.*

FDA Label Image

Image (Amjevita 25)

An instructional illustration depicting a bandage and three cotton balls. The image likely relates to preparation or care steps for a subcutaneous injection, such as applying a bandage and using cotton balls for cleaning or pressure after injection.*

FDA Label Image

Image (Amjevita 26)

A labeled illustration of an AMJEVITA (adalimumab-atto) 40 mg/0.4 mL subcutaneous injection pen. Labels indicate key components: light blue start button, expiration date area, window showing medicine and plunger position, cream safety guard containing the needle, and yellow cap at the base.*

FDA Label Image

Image (Amjevita 27)

An instructional diagram illustrating how to store AMJEVITA prefilled syringes or pens by refrigerating them in their carton until ready for use. The image shows a refrigerator with an arrow pointing to the closed carton inside.*

FDA Label Image

Image (Amjevita 28)

An illustration of a clock face showing the time interval "15-30 minutes." The clock has simple black markings for hours and minutes on a white background, with the interval text prominently in the center.*

FDA Label Image

Image (Amjevita 29)

An illustration of a calendar page showing the number 14 and the word 'days' below it, likely indicating a two-week period. The calendar is stylized with two loops at the top suggesting binding or hanging.*

FDA Label Image

Image (Amjevita 30)

Illustration of an AMJEVITA injection pen showing a close-up view of the dose window where the medicine level is visible. The pen is blue with a yellow cap, and the window displays the medication inside for subcutaneous administration.*

FDA Label Image

Image (Amjevita 31)

An instructional diagram showing the location of the expiration date on an AMJEVITA (adalimumab-atto) subcutaneous injection pen. The expiration date is indicated on the side of the injection device near the labeled lot number.*

FDA Label Image

Image (Amjevita 32)

An instructional illustration showing a sharps disposal container alongside labeled items for use with injections: an alcohol wipe, adhesive bandage, and cotton ball or gauze pad. The image highlights essential supplies for safe injection practices and disposal.*

FDA Label Image

Image (Amjevita 33)

An illustration diagram showing recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto). The highlighted areas for injection include the abdomen around the navel and the front of the thighs, indicated by blue shaded regions on a human figure.*

FDA Label Image

Image (Amjevita 34)

An instructional illustration showing two hands with soap bubbles, demonstrating the action of hand washing or hand scrubbing. The image emphasizes proper hand hygiene technique.*

FDA Label Image

Image (Amjevita 35)

An instructional illustration showing a hand pressing on a square pad, likely demonstrating the application or preparation step related to a medication injection or patch.*

FDA Label Image

Image (Amjevita 36)

An instructional diagram showing a hand holding an AMJEVITA subcutaneous injection pen with the cap being removed. The image highlights that the window on the pen should be visible before use, illustrating proper preparation steps for injection.*

FDA Label Image

Image (Amjevita 37)

An instructional diagram showing a hand holding a pen-like injection device poised to inject into the skin, with an arrow and label indicating to pinch the skin at the injection site. This illustrates the proper subcutaneous injection technique for the medication.*

FDA Label Image

Image (Amjevita 38)

An instructional illustration showing a blue pen-like device for subcutaneous injection. The two-panel diagram depicts pressing the device vertically downward onto the skin and performing a subsequent action, likely indicating injection steps or confirmation. The images emphasize proper positioning and technique for administering the injection.*

FDA Label Image

Image (Amjevita 39)

Instructional illustration showing a hand pressing down on the top of an injection pen or device, indicated by a downward arrow. This suggests the action required to activate or use the injection device for subcutaneous administration.*

FDA Label Image

Image (Amjevita 40)

An instructional illustration showing the use of the AMJEVITA adalimumab-atto subcutaneous injection pen. It depicts a hand pressing the pen down onto the skin to deliver the injection, with close-up views highlighting the window indicator changing color to show medication delivery progress.*

FDA Label Image

Image (Amjevita 41)

An instructional illustration showing the use of an injection pen device, identified as AMJEVITA (adalimumab-atto) injection for subcutaneous use. The image depicts a cap being removed from a container, with an arrow indicating the direction, and the injection pen positioned nearby, highlighting steps in the medication preparation process.*

FDA Label Image

Image (Amjevita 42)

An illustration showing a single adhesive bandage with a rectangular pad in the center and ventilation holes on the sides, above three irregularly shaped cotton balls. The diagram appears instructional or related to first aid or injection site care.*

FDA Label Image

Image (Amjevita 43)

An instructional diagram of AMJEVITA 80 mg/0.8 mL injection pen showing labeled parts including a light blue start button, expiration date window, visible medicine window with plunger, cream safety guard containing the needle, and a yellow cap at the base.*

FDA Label Image

Image (Amjevita 44)

An instructional illustration showing how to store the AMJEVITA injection. It depicts a carton being opened, with text advising to refrigerate the carton until ready to use.*

FDA Label Image

Image (Amjevita 45)

An illustration depicting a clock face showing a time range labeled as "15-30 minutes." The clock face includes tick marks around the perimeter without numbers. This image likely indicates a time interval or duration relevant to the product.*

FDA Label Image

Image (Amjevita 46)

An illustration of a calendar page showing the text '14 days' in bold, indicating a two-week period. The calendar graphic has a blue top and white page background.*

FDA Label Image

Image (Amjevita 47)

An illustration showing a vertical injection device or syringe, color-coded mainly in blue with a yellow base, labeled with a zoomed-in inset highlighting the medicine compartment. The inset includes a pointer labeled 'Medicine' indicating the fluid inside the device, demonstrating the part of the injection containing the medication.*

FDA Label Image

Image (Amjevita 48)

An instructional illustration showing a blue pen injector device with a yellow tip, indicating where to find the lot number and expiration date on its label. The expiration date area is highlighted and labeled for easy identification.*

FDA Label Image

Image (Amjevita 49)

An instructional illustration showing a sharps disposal container alongside individual items including an alcohol wipe, adhesive bandage, and cotton ball or gauze pad. The diagram labels each item clearly, indicating their use in medical injection or post-injection care.*

FDA Label Image

Image (Amjevita 50)

Illustration showing recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto) on a human figure. Highlighted areas include the abdomen, front of the thighs, and outer upper arms, indicating appropriate locations for injection administration.*

FDA Label Image

Image (Amjevita 51)

An instructional illustration depicting a pair of hands being washed, with soap bubbles indicating thorough cleaning. The image likely represents hand hygiene practices.*

FDA Label Image

Image (Amjevita 52)

An instructional illustration depicting a hand holding and peeling back a protective cover, likely showing how to open a medication package or prepare a device for use.*

FDA Label Image

Image (Amjevita 53)

An instructional illustration showing a hand holding an AMJEVITA injection pen with a removable yellow cap. The image highlights that the window on the injection pen should be visible when in use, indicated by a blue arrow and text. This diagram is likely intended to guide correct handling or use of the subcutaneous injection pen.*

FDA Label Image

Image (Amjevita 54)

An instructional diagram showing a hand administering a subcutaneous injection with an injection pen. The illustration highlights pinching the skin at the injection site on the forearm to prepare for injection.*

FDA Label Image

Image (Amjevita 55)

An instructional illustration showing a two-step process with a blue medical device or syringe tip being positioned above a surface. The first image shows the device with its cap intact, and the second image shows the device after the cap is removed, indicated by an arrow pointing downward. This likely depicts preparation steps for injection.*

FDA Label Image

Image (Amjevita 56)

An instructional illustration showing a hand gripping a small injection device or pen, with a downward arrow indicating the direction of pressing or pushing on the device. This image likely relates to the subcutaneous injection preparation or administration technique for AMJEVITA (adalimumab-atto) injection.*

FDA Label Image

Image (Amjevita 57)

An instructional illustration showing the use of a subcutaneous injection pen labeled AMJEVITA (adalimumab-atto). The image depicts a hand pressing the pen vertically into the skin and close-ups of the window on the pen, indicating a visual progress marker before and after injection.*

FDA Label Image

Image (Amjevita 58)

Illustration showing the preparation of an injection pen device by attaching a yellow needle to the pen. A blue arrow indicates inserting the needle into an open container with a white lid, demonstrating the setup process for a subcutaneous injection pen.*

FDA Label Image

Image (Amjevita 59)

An instructional illustration showing a rectangular adhesive bandage with rounded corners and ventilation holes along the sides, alongside three cotton balls. The image suggests the use of these items for post-injection care or preparation.*

FDA Label Image

Principal Display Panel (20 mg/0.2 mL Syringe Carton)

AMJEVITA 20 mg/0.2 mL injection is a single-dose prefilled syringe for subcutaneous use, containing adalimumab-atto. The sterile solution is preservative-free and must be refrigerated between 2°C to 8°C (36°F to 46°F). The label highlights pediatric use for patients 15 to less than 30 kg and specifies it is not made with natural rubber latex. Manufactured for Nuvaila Limited.*

FDA Label Image

Principal Display Panel (40 mg/0.4 mL Syringe Carton)

AMJEVITA 40 mg/0.4 mL subcutaneous injection label displays the brand and generic name adalimumab-atto. It highlights two single-dose prefilled syringes per package, storage instructions to keep refrigerated at 2°C to 8°C, and cautions such as no shaking or freezing. The label notes it is a sterile solution with no preservative, not made with natural rubber latex, and manufactured for Nuvaila Limited.*

FDA Label Image

Principal Display Panel (40 mg/0.4 mL Autoinjector Carton)

AMJEVITA 40 mg/0.4 mL injection carton label for subcutaneous use, containing two single-dose prefilled SureClick autoinjectors. The label includes storage instructions specifying refrigeration between 2°C to 8°C (36°F to 46°F), and cautions to not freeze or shake. It is manufactured for Nuvaila Limited and states the product is sterile without preservatives and does not contain natural rubber latex.*

FDA Label Image

Principal Display Panel (80 mg/0.8 mL Autoinjector Carton)

AMJEVITA 80 mg/0.8 mL injection for subcutaneous use, containing adalimumab-atto. The label shows two single-dose prefilled SureClick autoinjectors. It includes storage instructions to refrigerate at 2°C to 8°C (36°F to 46°F), warnings against freezing, shaking, and re-use, plus a caution to protect from light. Manufactured for Nuvaila Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.